Literature DB >> 11737509

Effect of a polyhexamethylene biguanide mouthrinse on bacterial counts and plaque.

M Rosin1, A Welk, O Bernhardt, M Ruhnau, F A Pitten, T Kocher, A Kramer.   

Abstract

OBJECTIVES: For various clinical applications, polyhexamethylene biguanide (PHMB) has been used for many years as an antiseptic in medicine. Little is known, however, of its antibacterial activity in the oral cavity and its ability to inhibit plaque formation. In this study, a 0.04% PHMB mouthrinse (A) was compared with a negative control placebo rinse (10% ethanol, flavour) (B) and 2 positive control chlorhexidine rinses, one of which was a 0.12% aqueous solution (C) and the other a commercially available mouthrinse (Skinsept mucosa) diluted to a chlorhexidine concentration of 0.12% (D).
MATERIAL AND METHODS: The study was a double-blind, randomised 4-replicate 4 x 4 Latin square cross-over design. Plaque regrowth was assessed with the Turesky et al. modification of the Quigley and Hein plaque index. The in vivo antibacterial effect was assessed by taking bacterial counts from the tooth surface (smears from the lingual surface of 16) and mucosa (smears from the buccal mucosa) 4 h after the 1st rinse with the preparations on day 1 and prior to the clinical examination on day 5. 16 volunteers participated, and on day 1 of each study period were rendered plaque-free, ceased toothcleaning, and rinsed 2x daily with the allocated mouthrinse. On day 5, plaque was scored and smears were collected according to the protocol. Washout periods were 9 days. Data were analysed using ANOVA with Tukey HSD adjustment for multiple comparisons (significance level alpha=0.05).
RESULTS: Mouthrinses A, C, and D were significantly more effective in inhibiting plaque than the placebo (B). Mouthrinse C was significantly better than mouthrinses A and D, while mouthrinses D and A were equally effective in inhibiting plaque. Bacterial count reductions on the tooth surface with mouthrinse C were significantly greater compared to mouthrinse A and the placebo (B). The reduction of bacterial counts on the mucosa with C was significantly greater than with A and B after 4 h and significantly greater than with A, B and D after 5 days. Mouthrinse A reduced bacteria on the mucosa significantly more effectively than the placebo (B) after 4 h and 5 days, while mouthrinse D was more effective than the placebo (B) after 4 h.
CONCLUSION: The results indicate that a 0.04% PHMB mouthwash inhibits plaque regrowth and reduces oral bacterial counts, and may be used in preventive applications in the oral cavity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11737509     DOI: 10.1034/j.1600-051x.2001.281206.x

Source DB:  PubMed          Journal:  J Clin Periodontol        ISSN: 0303-6979            Impact factor:   8.728


  18 in total

1.  Structure-activity relationships of polybiguanides with activity against human immunodeficiency virus type 1.

Authors:  Shendra R Passic; Mary Lee Ferguson; Bradley J Catalone; Tina Kish-Catalone; Vladyslav Kholodovych; Wei Zhu; William Welsh; Robert Rando; Mary K Howett; Brian Wigdahl; Mohamed Labib; Fred C Krebs
Journal:  Biomed Pharmacother       Date:  2010-11-04       Impact factor: 6.529

2.  Polypragmasia in the therapy of infected wounds - conclusions drawn from the perspectives of low temperature plasma technology for plasma wound therapy.

Authors:  Axel Kramer; Nils-Olaf Hübner; Klaus-Dieter Weltmann; Jürgen Lademann; Axel Ekkernkamp; Peter Hinz; Ojan Assadian
Journal:  GMS Krankenhhyg Interdiszip       Date:  2008-11-03

3.  Specific interactions between the viral coreceptor CXCR4 and the biguanide-based compound NB325 mediate inhibition of human immunodeficiency virus type 1 infection.

Authors:  Nina Thakkar; Vanessa Pirrone; Shendra Passic; Wei Zhu; Vladyslav Kholodovych; William Welsh; Robert F Rando; Mohamed E Labib; Brian Wigdahl; Fred C Krebs
Journal:  Antimicrob Agents Chemother       Date:  2008-12-01       Impact factor: 5.191

4.  Antibacterial and antiplaque efficacy of a commercially available octenidine-containing mouthrinse.

Authors:  Alexander Welk; Maral Zahedani; Carolin Beyer; Axel Kramer; Gerald Müller
Journal:  Clin Oral Investig       Date:  2015-11-10       Impact factor: 3.573

5.  Polyhexamethylene biguanide functionalized cationic silver nanoparticles for enhanced antimicrobial activity.

Authors:  Sumaira Ashraf; Nasrin Akhtar; Muhammad Afzal Ghauri; Muhammad Ibrahim Rajoka; Zafar M Khalid; Irshad Hussain
Journal:  Nanoscale Res Lett       Date:  2012-05-24       Impact factor: 4.703

6.  The resistance of the yeast Saccharomyces cerevisiae to the biocide polyhexamethylene biguanide: involvement of cell wall integrity pathway and emerging role for YAP1.

Authors:  Carolina Elsztein; Rodrigo M de Lucena; Marcos A de Morais
Journal:  BMC Mol Biol       Date:  2011-08-19       Impact factor: 2.946

7.  Cervicovaginal safety of the formulated, biguanide-based human immunodeficiency virus type 1 (HIV-1) inhibitor NB325 in a murine model.

Authors:  Karissa Lozenski; Tina Kish-Catalone; Vanessa Pirrone; Robert F Rando; Mohamed Labib; Brian Wigdahl; Fred C Krebs
Journal:  J Biomed Biotechnol       Date:  2011-10-24

8.  Comparison on the Efficacy of Disinfectants Used in Automated Endoscope Reprocessors: PHMB-DBAC versus Orthophthalaldehyde.

Authors:  Sun Young Kim; Hong Sik Lee; Jong Jin Hyun; Min Ho Seo; Sun Young Yim; Ha Young Oh; Hye Sook Kim; Bora Keum; Yeon Seok Seo; Yong Sik Kim; Yoon Tae Jeen; Hoon Jai Chun; Soon Ho Um; Chang Duck Kim; Ho Sang Ryu
Journal:  Clin Endosc       Date:  2011-12-31

Review 9.  Cationic antimicrobial polymers and their assemblies.

Authors:  Ana Maria Carmona-Ribeiro; Letícia Dias de Melo Carrasco
Journal:  Int J Mol Sci       Date:  2013-05-10       Impact factor: 5.923

10.  Surface characterization and frictional force between stainless steel brackets and archwires in orthodontic patients using chlorhexidine- and Persica-containing mouthrinses: A randomized controlled trial.

Authors:  Elham-Sadat Emadian Razavi; Tahereh Hosseinzadeh Nik; Tabassom Hooshmand; Habibeh Farazdaghi; Arian Hesam Arefi
Journal:  Dent Res J (Isfahan)       Date:  2021-04-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.